Drug Information

Drug General Information
Drug ID
D0J7RK
Former ID
DAP000245
Drug Name
Dobutamine
Synonyms
Dobutamina; Dobutaminum; Dobutamine Hcl; Dobutamine [USAN]; Dobutamine hydrobromide; LY 81929; Lilly 81929; DL-dobutamine; Dobutamina [INN-Spanish]; Dobutamine Hcl in Dextrose 5%; Dobutamine(usp); Dobutaminum [INN-Latin]; Rac-dobutamine; Racemic-Dobutamine; Dobutamine (USP/INN); Dobutamine [USAN:BAN:INN]; Dobutamine Tartrate (1:1), (S-(R*,R*))-Isomer; (+-)-4-(2-((3-(p-Hydroxyphenyl)-1-methylpropyl)amino)ethyl)pyrocatechol; 3,4-dihydroxy-N-[3-(4-hydroxyphenyl)-1-methylpropyl]-beta-phenylethylamine; 4-(2-{[3-(4-hydroxyphenyl)-1-methylpropyl]amino}ethyl)benzene-1,2-diol; 4-(2-{[4-(4-hydroxyphenyl)butan-2-yl]amino}ethyl)benzene-1,2-diol; 4-[2-[4-(4-hydroxyphenyl)butan-2-ylamino]ethyl]benzene-1,2-diol
Drug Type
Small molecular drug
Indication Heart failure; Cardiogenic shock [ICD9: 428.0, 785.51; ICD10:I50, R57.0] Approved [538260], [540787]
Therapeutic Class
Cardiotonic Agents
Company
Ben Venue Laboratories
Structure
Download
2D MOL

3D MOL
Formula
C18H23NO3
InChI
InChI=1S/C18H23NO3/c1-13(2-3-14-4-7-16(20)8-5-14)19-11-10-15-6-9-17(21)18(22)12-15/h4-9,12-13,19-22H,2-3,10-11H2,1H3
InChIKey
JRWZLRBJNMZMFE-UHFFFAOYSA-N
CAS Number
CAS 34368-04-2
PubChem Compound ID
36811
PubChem Substance ID
9181, 5680486, 7979113, 8174668, 11466380, 11467500, 11486100, 14825296, 17397963, 26751752, 34678180, 46505241, 47434355, 47879635, 47953969, 48104696, 48253451, 48415917, 49698448, 50064706, 50104446, 53788487, 57311932, 78153929, 85209842, 85788850, 90341592, 92308881, 99313634, 103241510, 104171143, 104324888, 117616952, 117646595, 124749655, 124879838, 124879839, 124879840, 124879841, 124879842, 128318768, 134337559, 134998867, 135650199, 137241858, 142059874, 144203677, 160964182, 163882666, 170465050
SuperDrug ATC ID
C01CA07
SuperDrug CAS ID
cas=034368042
Target and Pathway
Target(s) Beta-1 adrenergic receptor Target Info Agonist [536628], [537916]
KEGG Pathway Calcium signaling pathway
cGMP-PKG signaling pathway
cAMP signaling pathway
Neuroactive ligand-receptor interaction
Endocytosis
Adrenergic signaling in cardiomyocytes
Gap junction
Salivary secretion
Dilated cardiomyopathy
PANTHER Pathway Heterotrimeric G-protein signaling pathway-Gi alpha and Gs alpha mediated pathway
Beta1 adrenergic receptor signaling pathway
PathWhiz Pathway Muscle/Heart Contraction
Reactome Adrenoceptors
G alpha (s) signalling events
WikiPathways Monoamine GPCRs
Calcium Regulation in the Cardiac Cell
GPCRs, Class A Rhodopsin-like
Endothelin Pathways
GPCR ligand binding
GPCR downstream signaling
References
Ref 538260FDA Approved Drug Products from FDA Official Website. 2009. Application Number: (ANDA) 074086.
Ref 540787(http://www.guidetopharmacology.org/) Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 535).
Ref 536628Beta-adrenoceptor alterations coupled with secretory response and experimental periodontitis in rat submandibular glands. Arch Oral Biol. 2008 Jun;53(6):509-16. Epub 2008 Feb 13.
Ref 537916Autoimmunity in idiopathic dilated cardiomyopathy. Characterization of antibodies against the beta 1-adrenoceptor with positive chronotropic effect. Circulation. 1994 Jun;89(6):2760-7.

If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.